$生化基因(BIIB)$
The  market  re-rating  of  BIIB  to  $300  closing  price  is  now where there is fundamental DCF support of the base business alone at $290-300...implying  buyers  at  these  levels  are  nearly  getting  the  huge pipeline for almost free long-term.

Longer-term investors should look at BIIB as this provides an attractive area now, with reset expectations, full pipeline, and capital deployment opportunities...